Stay updated on Durvalumab Plus Chemotherapy in Operable Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Durvalumab Plus Chemotherapy in Operable Urothelial Cancer Clinical Trial page.

Latest updates to the Durvalumab Plus Chemotherapy in Operable Urothelial Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedRevision tag updated to v3.3.2; the previous v3.2.0 tag was removed.SummaryDifference0.0%

- Check27 days agoChange DetectedRemoved the government funding/operating status notice that previously warned users information may not be up to date and that NIH operations could be affected.SummaryDifference0.3%

- Check49 days agoChange DetectedMinor visual/layout adjustments and a more recent last-updated timestamp, with core study details unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check63 days agoChange DetectedAdded a full Neoadjuvant/Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy study (SAKK 06/17), detailing objective, design, criteria, endpoints, and locations; no deletions were reported.SummaryDifference100%

- Check70 days agoChange DetectedUpdated core page content to reflect a version bump to v3.2.0 and a government-operating-status notice; removed the previous v3.1.0 version tag.SummaryDifference3%

- Check78 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0; a minimal change primarily affecting the page's revision metadata.SummaryDifference0.1%

Stay in the know with updates to Durvalumab Plus Chemotherapy in Operable Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab Plus Chemotherapy in Operable Urothelial Cancer Clinical Trial page.